Clinical outcomes with commercial teclistamab. (A) Swimmer plot for patients responding to teclistamab colored by treatment response according to IMWG criteria, with “→” designating ongoing treatment response as of the data cutoff. (B) PFS for all patients treated with commercial teclistamab. (C) PFS with teclistamab stratified by BCMA therapy exposure. (D) PFS for patients exposed to BCMA therapy with >200 days since their most recent anti-BCMA therapy vs <200 days since their most recent anti-BCMA therapy. IMWG, International Myeloma Working Group.